Skip to main content

20-06-2022 | EULAR 2022 | Conference coverage | Video

BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials (3:02).